LA
TEVA icon

Linden Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

Linden Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-200,000
Closed -$3.79M – 147
2017
Q4 		$3.79M Buy
+200,000
New +$3.01M 0.11% 95

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NC
Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Linden Advisors's TEVA Position: Q1 2018 in Review

Linden Advisors sold out of Teva Pharmaceuticals (TEVA) in Q1 2018, closing a stake of 200,000 shares — an estimated $3.79M sold.

Linden Advisors first reported a position in TEVA in Q4 2017 and held it in 1 quarter. The position peaked at $3.79M in Q4 2017. 506 funds tracked by Wall St. Rank hold TEVA as of Q1 2018.

  • Linden Advisors reported no remaining Teva Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Linden Advisors sold 200,000 Teva Pharmaceuticals shares in Q1 2018, an estimated $3.79M.
  • Linden Advisors first reported a position in Teva Pharmaceuticals in Q4 2017 and held it in 1 quarter.
  • Linden Advisors's Teva Pharmaceuticals position peaked at $3.79M in Q4 2017.
  • 506 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2018.

Based on Linden Advisors's 13F filing for Q1 2018, filed 15 May 2018.